Table 5.
Estimated odds ratio (95% confidence interval) from the multivariate analysis of baseline, age, tumour type and tipifarnib AUC and treatment duration as predictor of nonhaematological toxicities
| Liver and renal toxicities | AST | ALT | Bilirubin | Creatinine |
|---|---|---|---|---|
| Baseline (Grade ≥1 vs Grade 0) | 3.50 (2.53, 4.85)* | 2.86 (2.07, 3.94)* | 2.48 (1.87, 3.31)* | 2.68 (1.96, 3.65)* |
| Age (≥65 years vs. <65 years) | 0.53 (0.27, 1.04) | 0.52 (0.26, 1.06) | 0.58 (0.36, 0.93)* | 0.98 (0.57, 1.69) |
| Cancer type (r-AML vs. solid tumour) | 1.41 (0.62, 3.23) | 1.33 (0.60, 2.95) | 1.30 (0.74, 2.29) | 4.37 (2.31, 8.27)* |
| Exposure (AUC, mg l−1 h) | 0.88 (0.78, 0.99)* | 0.93 (0.82, 1.04) | 0.98 (0.91, 1.06) | 1.07 (0.99, 1.15) |
| Treatment duration (weeks) | 1.05 (0.99, 1.11) | 1.03 (0.97, 1.10) | 1.07 (1.02, 1.11)* | 1.12 (1.07, 1.18)* |
| GI toxicities | Nausea and vomiting | Diarrhoea | GI inflammation |
|---|---|---|---|
| Age (≥65 years vs. <65 years) | 0.63 (0.43, 0.93)* | 1.02 (0.64, 1.64) | 0.74 (0.54, 1.02) |
| Cancer type (r-AML vs. solid tumour) | 1.55 (0.97, 2.49) | 1.59 (0.90, 2.83) | 1.72 (1.14, 2.59)* |
| Exposure (AUC, mg l−1 h) | 0.99 (0.93, 1.05) | 1.11 (1.03, 1.19)* | 1.02 (0.97, 1.08) |
| Treatment duration (weeks) | 0.95 (0.92, 0.98)* | 0.98 (0.94, 1.01) | 1.00 (0.98, 1.02) |
| Other toxicities | Skin rash | CNS toxicity | Peripheral neurotoxicity |
|---|---|---|---|
| Age (≥65 years vs. <65 years) | 0.99 (0.59, 1.64) | 1.04 (0.73, 1.49) | 1.63 (0.93, 2.84) |
| Cancer type (r-AML vs. solid tumour) | 1.93 (1.03, 3.63)* | 0.91 (0.58, 1.43) | 1.67 (0.84, 3.30) |
| Exposure (AUC, mg l−1 h) | 1.05 (0.98, 1.13) | 1.06 (1.00, 1.12) | 1.07 (0.98, 1.16) |
| Treatment duration (week) | 0.91 (0.86, 0.96)* | 0.96 (0.93, 0.98)* | 1.03 (1.01, 1.06)* |
*
p < 0.05.